Global speaker programmes
For patients to benefit from new medical innovations, HCPs need to access and understand the latest available data and clinical use of the product.
Feedback from HCPs shows that they prefer to learn about new data and clinical experience through peer-to-peer programmes with global expert practitioners who have direct experience with our medicines.
To help HCPs share new data on our products and understand their clinical use, in some cases we:
- make fair market value payments to global expert practitioners who speak about the new science behind selected GSK products, their associated diseases and clinical practice in promotional settings
- pay reasonable travel costs (except in the US) for an HCP to attend a GSK-organised standalone meeting to learn about data and clinical expertise.
- directly pay registration fees for HCPs to attend remote congress webinars/webcasts. We do not sponsor HCPs to attend local and international conferences.
This policy is limited to select products in certain countries around the world and controls and training are in place, including measures to track appropriate payment and use of external speakers.
Where legally permitted, we will report individual-level payments made each year to HCPs for attending educational meetings and for the provision of services, such as speaking at events or attending advisory boards. Where individual level disclosure is not legally permitted, we will continue to report aggregate payments.
Collaborating on clinical trials and research
Healthcare professionals (HCPs) help us identify potential volunteers for clinical trials, administer the investigational medicine or vaccine to patients, and monitor the results.
All HCPs who work with us on clinical trials have contracts and are paid for their work on these clinical trials. This payment covers their time, plus the cost of investigations they may need to carry out regarding the suitability of a patient and the effectiveness of the treatment.
We have a commitment to publicly disclose the research payments that are made to healthcare professionals and to their institutions for conducting clinical research.
Disclosure reports
- Outside of Europe and the US, we continue to support transparency as industry associations or governments establish specific guidelines for disclosure. Where legally permitted, we disclose annually individual level payments for attending educational meetings and for the provision of services, such as speaking at events or attending advisory boards in the markets where these activities take place. Where individual level disclosure is not legally permitted, we will continue to report aggregate payments.
- In the US, we report our payments and other transfers of value to US Healthcare Professionals and US Healthcare Organisations we have worked with, in compliance with federal and state transparency laws. View the Federal CMS Open Payments data
- In Europe, we fully support and continue to implement the European Federation of Pharmaceutical Industries and Associations (EFPIA) Code on the disclosure of individual transfer of value from pharmaceutical companies to HCPs and HCOs. To affirm our commitment to the principles of the EFPIA Code of Practice we've signed this self-certification letter (PDF - 197KB).
- Algeria
- Argentina
- Austria
- Bahrain
- Belgium
- Bosnia and Herzegovina
- Brazil
- Bulgaria
- Chile
- Colombia
- Costa Rica
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Any engagement with a pharmaceutical company including zero payment engagements
- All R&D engagements by named disclosure
- Congress sponsorships (no amount disclosure)
- Dominican Republic
- Ecuador
- Egypt
- El Salvador
- Estonia
- Finland
- France
- Germany
- Greece
- Guatemala
- Hungary
- Honduras
- Kuwait
- Ireland
- Indonesia
- Israel
- Italy
- Jamaica
- Latvia
- Lithuania
- Luxembourg
- Malaysia
- Malta
- Mexico
- Morocco
- Netherlands
- North Macedonia
- Norway
- Oman
- Pakistan
- Panama
- Peru
- Philippines
- Poland
- Portugal
- Qatar
- Romania
- Russia
- Saudi Arabia
- Serbia and Montenegro
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Thailand
- Trinidad and Tobago
- Turkey
- Ukraine
- United Arab Emirates
- United Kingdom
- Vietnam
As part of our global corporate commitment to the highest standards of transparency and ethics in our business practices, GSK has decided to disclose payments or transfers of value to healthcare professionals for services provided to GSK, in accordance with the terms of contracts with such third parties. Such services include activities such as speaking at a conference, providing advice as a member of an expert advisory board or as a consultant, as well as travel and accommodation expenses associated with those services.
In 2023, GSK made payments totalling DZD 4,297,372.41 – and £ 25,278.66 to a total of 22 healthcare professionals with an average payment of DZD 195,335.11 – and £ 1,149.03 /HCP.
In 2022, GSK made payments totalling DZD 9,973,82.81/£ 5,866.96 to a total of 6 healthcare professionals with an average payment of DZD 166,230.47/£ 977.83 per HCP.
| Year | Report |
|---|---|
| 2023 | PDF (329KB) |
| 2022 | PDF (73KB) |
Media enquiries:
Please contact Salim Ait Belkacem, Corporate Government Affairs Head Algeria
| Contact details | |
|---|---|
|
Email: |
|
As part of our global corporate commitment to the highest standards of transparency and ethics in our business practices, GSK has decided to disclose payments or transfers of value to healthcare professionals for services provided to GSK, in accordance with the terms of contracts with such third parties. Such services include activities such as speaking at a conference, providing advice as a member of an expert advisory board or as a consultant, as well as travel and accommodation expenses associated with those services.
In 2023, GSK made payments totalling ARS 150,229,059.59 – £ 476,917.65 to a total of 208 healthcare professionals with an average payment of ARS 722,255.09 – £ 2,292.87 / HCP.
In 2022, GSK made payments totalling ARS 76,503,570.18/£ 437,163.26 to a total of 185 healthcare professionals with an average payment of ARS 413,532.81/£ 2,363.04 per HCP.
In 2021, GSK made payments totalling ARS 22,505,278.81 to a total of 143 healthcare professionals.
| Year | Report |
|---|---|
| 2023 | PDF (221KB) |
| 2022 | PDF (155KB) |
| 2021 | PDF (235KB) |
Media enquiries:
Please contact Piera Basile – Senior Communications and Government Affairs Manager
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Austria in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Deutsch |
|---|---|---|---|
| 2023 | PDF (247KB) | PDF (198KB) | PDF (180KB) |
| 2022 | PDF (208KB) | PDF (101KB) | PDF (105KB) |
| 2021 | PDF (199KB) | PDF (751KB) | PDF (656KB) |
Media enquiries:
Please contact Mag. Barbara Masser-Mayerl, Communications Manager
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
As part of our global corporate commitment to the highest standards of transparency and ethics in our business practices, GSK has decided to disclose payments or transfers of value to healthcare professionals for services provided to GSK, in accordance with the terms of contracts with such third parties. Such services include activities such as speaking at a conference, providing advice as a member of an expert advisory board or as a consultant, as well as travel and accommodation expenses associated with those services.
In 2023, GSK made payments totalling 15,555 BHD (32,665 £) to a total of 25 healthcare professionals with an average payment of 622 BHD (1,307 £) /HCP.
In 2022, GSK made payments totalling BHD 8,881/£ 19,006 to a total of 21 healthcare professionals with an average payment of BHD 423/£ 905 per HCP.
In 2021, we have paid BHD, 4,725 to a total number of 14 HCPs with an average payment of BHD 338 per HCP.
| Year | Report |
|---|---|
| 2023 | PDF (104KB) |
| 2022 | PDF (192KB) |
| 2021 | PDF (226KB) |
Media enquiries:
Please contact Averyan Vasylyev, Gulf Cluster Medical Director
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Belgium in line with the EFPIA code and pharma.be code, and to a note on the methodology used to set out the data in the report.
The significant presence of GSK Vaccines in Belgium, where the global centre for R&D (research & development) as well as the manufacturing site of vaccines, explain why some local collaborations with Healthcare Professionals and Organisations have an international dimension.
Media enquiries:
Please contact Elisabeth Van Damme
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
| Year | Report | Methodological Note English | Methodological Note Bosnian |
|---|---|---|---|
| 2023 | No transfer of values were made | ||
| 2022 | No transfer of values were made | ||
| 2021 | No transfer of values were made | ||
Media enquiries:
| Contact details | |
|---|---|
|
Email: |
|
As part of our global corporate commitment to the highest standards of transparency and ethics in our business practices, GSK has decided to disclose payments or transfers of value to healthcare professionals for services provided to GSK, in accordance with the terms of contracts with such third parties. Such services include activities such as speaking at a conference, providing advice as a member of an expert advisory board or as a consultant, as well as travel and accommodation expenses associated with those services.
In 2023, GSK made payments totalling R$ 10.307.475 – £ 1.598.059 to a total of 3.688 healthcare professionals with an average payment of R$ 2.795 – and £ 433 /HCP.
In 2022, GSK made payments totalling R$ 3,754,422/£ 528,792 to a total of 2,614 healthcare professionals with an average payment of R$ 1,436/£ 202 per HCP.
In 2021, we have paid R$ 1.015 milhão, to a total number of 142 HCPs with an average payment of R$ 7.148/HCP.
Media enquiries:
Please contact Ingrid Santos, Communications Affairs Manager Brazil
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Bulgaria in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note български |
|---|---|---|---|
| 2023 | PDF (117KB) | PDF (125KB) | PDF (110KB) |
| 2022 | PDF (117KB) | PDF (133KB) | PDF (181KB) |
| 2021 | PDF (122KB) | PDF (104KB) | PDF (102KB) |
Media enquiries:
| Contact details | |
|---|---|
|
Email: |
|
As part of our global corporate commitment to the highest standards of transparency and ethics in our business practices, GSK has decided to disclose payments or transfers of value to healthcare professionals for services provided to GSK, in accordance with the terms of contracts with such third parties. Such services include activities such as speaking at a conference, providing advice as a member of an expert advisory board or as a consultant, as well as travel and accommodation expenses associated with those services.
In 2023, GSK made payments totalling CLP 286,755,757.50 – 298,728.71 to a total of 144 healthcare professionals with an average payment of CLP, 2,125,374.96 – and £ 2,153.30 /HCP.
In 2022, GSK made payments totalling $89,039,097/£ 87,723.25 to a total of 55 healthcare professionals with an average payment of $ 1,413,319/£ 1,392.43 per HCP.
In 2021, we have paid CLP $39,033,792 to a total number of 44 HCPs with an average payment of CLP $756,368./HCP.
| Year | Report |
|---|---|
| 2023 | PDF (104KB) |
| 2022 | PDF (199KB) |
| 2021 | PDF (199KB) |
Media enquiries:
Please contact Mariella Francesca Parodi Soza, Communications & Government Affairs Head
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
As part of our global corporate commitment to the highest standards of transparency and ethics in our business practices, GSK has decided to disclose payments or transfers of value to healthcare professionals for services provided to GSK, in accordance with the terms of contracts with such third parties. Such services include activities such as speaking at a conference, providing advice as a member of an expert advisory board or as a consultant, as well as travel and accommodation expenses associated with those services.
In 2023, GSK made payments totalling COP$ 979,901,774.00/ £201,046.73 to a total of 88 healthcare professionals with an average payment of COP$ 11,135,247.73 / £ 2,284.62 /HCP.
In 2022, GSK made payments totalling COP$ 830,321,971/£ 166,731.32 to a total of 69 healthcare professionals with an average payment of COP$ 12,033,652/£ 2,416 per HCP.
In 2021, we have paid COP 160.733.320 to a total number of 30 HCPs with an average payment of COP 5.357.777/HCP.
Media enquiries:
Please contact Juan Fernando García, Communications and Government Affairs Head
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
As part of our global corporate commitment to the highest standards of transparency and ethics in our business practices, GSK has decided to disclose payments or transfers of value to healthcare professionals for services provided to GSK, in accordance with the terms of contracts with such third parties. Such services include activities such as speaking at a conference, providing advice as a member of an expert advisory board or as a consultant, as well as travel and accommodation expenses associated with those services.
In 2023, GSK made payments totalling $61,139.89 – £42,165.44 to a total of 37 healthcare professionals with an average payment of $1,652.43 – £1,139.61 /HCP.
In 2022, GSK made payments totalling $10,813.10/£7,457.31 to a total of 14 healthcare professionals with an average payment of $ 772.36/£ 532.67 per HCP.
Media enquiries:
Please contact Sabrina Mujica, Communications and Government Affairs Manager
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Croatia in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Hrvatski |
|---|---|---|---|
| 2023 | PDF (113KB) | PDF (126KB) | PDF (110KB) |
| 2022 | PDF (105KB) | PDF (212KB) | PDF (271KB) |
| 2021 | PDF (103KB) | PDF (105KB) | PDF (103KB) |
Media enquiries:
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Cyprus in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English |
|---|---|---|
| 2023 | PDF (106KB) | |
| 2022 | PDF (98KB) | |
| 2021 | No transfer of values were made | |
Media enquiries:
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Czech Republic in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Czech |
|---|---|---|---|
| 2023 | PDF (190KB) | PDF (117KB) | PDF (141KB) |
| 2022 | PDF (166KB) | PDF (172KB) | PDF (236KB) |
| 2021 | PDF (150KB) | PDF (21KB) | PDF (65KB) |
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
EFPIA has assessed the Danish legislation on disclosure (decree number L94/2013-14) to meet the requirements for transparency and has exempted Denmark from implementing the EFPIA Disclosure Code given the disclosures are already disclosed through the Danish Medicines Agency / Laegemiddelstyrelsen.
Legislation in Denmark requires HCPs to self-disclose:
Our disclosures in Denmark via Danish Medicines Agency / Laegemiddelstyrelsen include all transfers of value made by GSK to individual HCPs. Any payments to HCOs and hospitals in Denmark are disclosed on the Grants & Donations section on GSKPro and in a yearly report on the homepage of ENLI (The Ethical Comittee for the Pharmaceutical Industry).
Media enquiries:
Please contact Helle Hellberg, Head of External Affairs
| Contact details | |
|---|---|
|
Email: |
|
As part of our global corporate commitment to the highest standards of transparency and ethics in our business practices, GSK has decided to disclose payments or transfers of value to healthcare professionals for services provided to GSK, in accordance with the terms of contracts with such third parties. Such services include activities such as speaking at a conference, providing advice as a member of an expert advisory board or as a consultant, as well as travel and accommodation expenses associated with those services.
In 2023, GSK made payments totalling $67,664.62 – £46,665.26 to a total of 40 healthcare professionals with an average payment of $1,691.62 – £1,166.63 /HCP.
In 2022, GSK made payments totalling $6,517.13/£4,494.57 to a total of 11 healthcare professionals with an average payment of $592.47/£408.60 per HCP.
Media enquiries:
Please contact Sabrina Mujica, Communications and Government Affairs Manager
| Contact details | |
|---|---|
|
Email: |
|
As part of our global corporate commitment to the highest standards of transparency and ethics in our business practices, GSK has decided to disclose payments or transfers of value to healthcare professionals for services provided to GSK, in accordance with the terms of contracts with such third parties. Such services include activities such as speaking at a conference, providing advice as a member of an expert advisory board or as a consultant, as well as travel and accommodation expenses associated with those services.
In 2023, GSK made payments totalling USD 18,955.33 – and £ 13,395.22 to a total of healthcare 20 professionals with an average payment of USD 3,145.55 – and £ 2,491.92 /HCP.
In 2022, GSK made payments totaling USD 6,746.80/£5,475.26 to a total of 10 healthcare professionals with an average payment of USD 674.68/£547.52 per HCP.
Media enquiries:
Please contact Mariella Francesca Parodi Soza, Communications & Government Affairs Head
| Contact details | |
|---|---|
|
Email: |
|
As part of our global corporate commitment to the highest standards of transparency and ethics in our business practices, GSK has decided to disclose payments or transfers of value to healthcare professionals for services provided to GSK, in accordance with the terms of contracts with such third parties. Such services include activities such as speaking at a conference, providing advice as a member of an expert advisory board or as a consultant, as well as travel and accommodation expenses associated with those services.
In 2023, GSK made payments totalling [EGP 3,174,332 – and £ 144,282.80] to a total of [152] healthcare professionals with an average payment of [EGP 20,884 – and £ 949.26] /HCP.
In 2022, GSK made payments totalling EGP 760,854/£ 34,584.27 to a total of 20 healthcare professionals with an average payment of EGP 38,043/£ 1,729.21 per HCP.
| Year | Report |
|---|---|
| 2023 | PDF (184KB) |
| 2022 | PDF (188KB) |
Media enquiries
Please contact Omar Shoukry, Communications and Government Affairs Head Egypt
| Contact details | |
|---|---|
|
Email: |
|
As part of our global corporate commitment to the highest standards of transparency and ethics in our business practices, GSK has decided to disclose payments or transfers of value to healthcare professionals for services provided to GSK, in accordance with the terms of contracts with such third parties. Such services include activities such as speaking at a conference, providing advice as a member of an expert advisory board or as a consultant, as well as travel and accommodation expenses associated with those services.
In 2023, GSK made payments totalling $33,090.89 – £22,821.30 to a total of 22 healthcare professionals with an average payment of $1,504.13 – £1,037.33 /HCP.
In 2022, GSK made payments totalling $2,627.43/£1,812.02 to a total of 6 healthcare professionals with an average payment of $437.91/£302 per HCP.
Media enquiries:
Please contact Sabrina Mujica, Communications and Government Affairs Manager
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Estonia in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Eesti |
|---|---|---|---|
| 2023 | PDF (117KB) | PDF (127KB) | PDF (107KB) |
| 2022 | PDF (115KB) | PDF (232KB) | PDF (218KB) |
| 2021 | PDF (104KB) | PDF (118KB) | PDF (97KB) |
Media enquiries:
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Finland in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Suomeksi |
|---|---|---|---|
| 2023 | PDF (224KB) | PDF (130KB) | PDF (129KB) |
| 2022 | PDF (208KB) | PDF (157KB) | PDF (156KB) |
| 2021 | PDF (186KB) | PDF (145KB) | PDF (143KB) |
Media enquiries:
Please contact Anna Dammert, Communications Lead
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for France in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Français |
|---|---|---|---|
| 2023 | PDF (120KB) | PDF (111KB) | PDF (131KB) |
| 2022 | PDF (215KB) | PDF (173KB) | PDF (187KB) |
| 2021 | PDF (122KB) | PDF (99KB) | PDF (118KB) |
Media enquiries:
Please contact Victoria Morel, Media Communication Manager
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Germany in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Deutsch |
|---|---|---|---|
| 2023 | PDF (534KB) | PDF (160KB) | PDF (165KB) |
| 2022 | PDF (498KB) | PDF (182KB) | PDF (194KB) |
| 2021 | PDF (538KB) | PDF (153KB) | PDF (157KB) |
Media enquiries:
Please contact Pia Clary, Head of Communications
| Contact details | |
|---|---|
|
Tel: |
+49 152 53239052 |
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Greece in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Ελληνικά |
|---|---|---|---|
| 2023 | PDF (323KB) | PDF (135KB) | PDF (127KB) |
| 2022 | PDF (1450KB) | PDF (175KB) | PDF (172KB) |
| 2021 | PDF (295KB) | PDF (193KB) | PDF (187KB) |
Media enquiries:
Please contact Vasilia Papagiannopoulou, Government Affairs & Market Access Director
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
As part of our global corporate commitment to the highest standards of transparency and ethics in our business practices, GSK has decided to disclose payments or transfers of value to healthcare professionals for services provided to GSK, in accordance with the terms of contracts with such third parties. Such services include activities such as speaking at a conference, providing advice as a member of an expert advisory board or as a consultant, as well as travel and accommodation expenses associated with those services.
In 2023, GSK made payments totalling $36,670.33 – £25,289.88 to a total of 25 healthcare professionals with an average payment of $1,466.81 – £1,011.60 /HCP.
In 2022, GSK made payments totalling $6,290.49/£4,338.27 to a total 11 healthcare professionals with an average payment of $571.86/£394.39 per HCP.
Media enquiries:
Please contact Sabrina Mujica, Communications and Government Affairs Manager
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Hungary in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Magyar |
|---|---|---|---|
| 2023 | PDF (107KB) | PDF (125KB) | PDF (115KB) |
| 2022 | PDF (105KB) | PDF (233KB) | PDF (277KB) |
| 2021 | PDF (108KB) | PDF (87KB) | PDF (108KB) |
Media enquiries:
| Contact details | |
|---|---|
|
Email: |
|
As part of our global corporate commitment to the highest standards of transparency and ethics in our business practices, GSK has decided to disclose payments or transfers of value to healthcare professionals for services provided to GSK, in accordance with the terms of contracts with such third parties. Such services include activities such as speaking at a conference, providing advice as a member of an expert advisory board or as a consultant, as well as travel and accommodation expenses associated with those services.
In 2023, GSK made payments totalling $49,208.50 – £33,936.90 to a total of 26 healthcare professionals with an average payment of $1,892.63 – £1,305.27 /HCP.
In 2022, GSK made payments totalling $2,392.28/£1,649.85 to a total 7 healthcare professionals with an average payment of $341.75/£235.70 per HCP.
Media enquiries:
Please contact Sabrina Mujica, Communications and Government Affairs Manager
| Contact details | |
|---|---|
|
Email: |
|
As part of our global corporate commitment to the highest standards of transparency and ethics in our business practices, GSK has decided to disclose payments or transfers of value to healthcare professionals for services provided to GSK, in accordance with the terms of contracts with such third parties. Such services include activities such as speaking at a conference, providing advice as a member of an expert advisory board or as a consultant, as well as travel and accommodation expenses associated with those services.
In 2023, GSK made payments totalling 38,714 KWD (99,495 £) to a total of 84 healthcare professionals with an average payment of 461 KWD (1,184 £) /HCP.
In 2022, GSK made payments totalling KWD 30,201/£ 79,428 to a total of 50 healthcare professionals with an average payment of KWD 604/£ 1,589 per HCP.
In 2021, we have paid 11,540 KWD to a total number of 30 HCPs with an average payment of 385 KWD per HCP.
| Year | Report |
|---|---|
| 2023 | PDF (183KB) |
| 2022 | PDF (380KB) |
| 2021 | PDF (231KB) |
Media enquiries:
Please contact Averyan Vasylyev, Gulf Cluster Medical Director
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The link below will take you to our disclosures for Ireland in line with the EFPIA code and Irish Pharmaceutical Healthcare Association (IPHA) code, that we are making through IPHA.
http://www.transferofvalue.ie/
Media enquiries:
Please contact Marguerite O'Loughlin, Head of Communications and Government Affairs
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
As part of our global corporate commitment to the highest standards of transparency and ethics in our business practices, GSK has decided to disclose payments or transfers of value to healthcare professionals for services provided to GSK, in accordance with the terms of contracts with such third parties. Such services include activities such as speaking at a conference, providing advice as a member of an expert advisory board or as a consultant, as well as travel and accommodation expenses associated with those services.
In 2023, GSK made payments totalling Rp 7,552,044,439,- or £394,177 to a total of 1226 healthcare professionals with an average payment of Rp 6,159,906,- or £322/HCP.
In 2022, GSK made payments totalling Rp 1,657,844,430/£86,531 to a total of 236 healthcare professionals with an average payment of Rp 7,024,765/£367 per HCP.
Media enquiries:
Please contact Reswita Dery Gisriani, Director of Market Access, Communication and Government Affairs
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Israel in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English |
|---|---|---|
| 2023 | PDF (156KB) | PDF (73KB) |
| 2022 | PDF (129KB) | PDF (161KB) |
| 2021 | PDF (77KB) | PDF (112KB) |
Media enquiries:
Please contact Margalit Keren, Communications Manager
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Italy in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
A specific focus on 2023 VIIV Healthcare TOV in favour of Italian HCPs and HCOs in Italy is available on ViiV Healthcare Italy.
| Year | Report | Methodological Note English | Methodological Note Italiano |
|---|---|---|---|
| 2023 | PDF (1.1MB) | PDF (151KB) | PDF (134KB) |
| 2022 | PDF (767KB) | PDF (184KB) | PDF (224KB) |
| 2021 | PDF (846KB) | PDF (121KB) | PDF (102KB) |
Media enquiries:
Please contact Massimo Ascani, External Communications Director
| Contact details | |
|---|---|
|
Email: |
|
As part of our global corporate commitment to the highest standards of transparency and ethics in our business practices, GSK has decided to disclose payments or transfers of value to healthcare professionals for services provided to GSK, in accordance with the terms of contracts with such third parties. Such services include activities such as speaking at a conference, providing advice as a member of an expert advisory board or as a consultant, as well as travel and accommodation expenses associated with those services.
In 2023, GSK made payments totalling $27,086.83 – £18,680.57 to a total of 19 healthcare professionals with an average payment of $1,425.62 – £983.19 /HCP.
In 2022, GSK made payments totalling $1,376.52/£949.32 to a total of 2 healthcare professionals with an average payment of $688.26/£474.66 per HCP.
Media enquiries:
Please contact Sabrina Mujica, Communications and Government Affairs Manager
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
Please find latest local disclosure report combining data from different companies published by Latvian Health Inspectorate.
A distributor SIA TAMRO (“Phoenix”) is involved in the promotion of medicines on behalf of GSK in Latvia. Transfers of Value made to HCPs / HCOs are reported separately by SIA TAMRO and should be considered together with transfers of value made by GSK directly.
The links below will take you to our previous year’s disclosures for Latvia in line with the EFPIA code, published on the Latvian Health Inspectorate website since 2021.
| Year | Report |
|---|---|
| 2023 | Transfers of value available on the Latvian Health Inspectorate |
| 2022 | Transfers of value available on the Latvian Health Inspectorate |
| 2021 | Transfers of value available on the Latvian Health Inspectorate |
Media enquiries:
| Contact details | |
|---|---|
| Email: | WW.CEEurope-media@gsk.com |
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
New local disclosure report will be published on State Medicines Control Agency Lithuania website by August 1, 2023 for ToVs to HCPs, and by November 1, 2023 for ToVs to HCOs. A distributor UAB „Tamro“ (“Phoenix”) is involved in the promotion of medicines on behalf of GSK in Lithuania. Transfers of Value made to HCPs / HCOs are reported separately by UAB TAMRO and should be considered together with transfers of value made by GSK directly.
Additionally, transfers of value made by GSK to HCOs reported on the State Medicines Control Agency, Lithuania, should be considered together with transfers of value made by GSK that are not reportable to the State Medicines Control Agency, Lithuania, and provided in the report below.
The links below will take you to our disclosures for Lithuania in line with the EFPIA code and IFPA, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Lietuvos |
|---|---|---|---|
| 2023 | PDF (99KB) | PDF (132KB) | PDF (117KB) |
| 2022 | PDF (99KB) | PDF (166KB) | PDF (153KB) |
| 2021 | PDF (158KB) | PDF (125KB) | PDF (93KB) |
Media enquiries:
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Luxembourg in line with the EFPIA code and IML code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Français |
|---|---|---|---|
| 2023 | PDF (112KB) | PDF (176KB) | PDF (182KB) |
| 2022 | PDF (104KB) | PDF (737KB) | PDF (751KB) |
| 2021 | PDF (96KB) | PDF (176KB) | PDF (101KB) |
Media enquiries:
Please contact Elisabeth Van Damme
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
As part of our global corporate commitment to the highest standards of transparency and ethics in our business practices, GSK has decided to disclose payments or transfers of value to healthcare professionals for services provided to GSK, in accordance with the terms of contracts with such third parties. Such services include activities such as speaking at a conference, providing advice as a member of an expert advisory board or as a consultant, as well as travel and accommodation expenses associated with those services.
In 2023, GSK made payments totalling RM 359,569.99 (£65,614.96) to a total of 149 healthcare professionals with an average payment of RM 2,413.22 (£440.37)/HCP.
In 2022, GSK made payments totalling RM 164,972.05/£ 30,104.39 to a total of 88 healthcare professionals with an average payment of RM 1,874.68/£342.10 per HCP.
In 2021, we have paid RM 57,000 to a total number of 34 HCPs.
| Year | Report |
|---|---|
| 2023 | PDF (182KB) |
| 2022 | PDF (382KB) |
| 2021 | PDF (102KB) |
Media enquiries:
Please contact David Lin, Director, Communications, Government Affairs & Strategic Customer Solutions
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Malta in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English |
|---|---|---|
| 2023 |
No transfer of values were made |
|
| 2022 |
No transfer of values were made |
|
| 2021 |
No transfer of values were made |
|
Media enquiries:
| Contact details | |
|---|---|
|
Email: |
|
As part of our global corporate commitment to the highest standards of transparency and ethics in our business practices, GSK has decided to disclose payments or transfers of value to healthcare professionals for services provided to GSK, in accordance with the terms of contracts with such third parties. Such services include activities such as speaking at a conference, providing advice as a member of an expert advisory board or as a consultant, as well as travel and accommodation expenses associated with those services.
In 2023, GSK made payments totalling MXN $8,544,346 - £348,749 to a total of 156 Healthcare Professionals with an average of payment of MXN $54,771 - £2,236 /HCP.
In 2022, GSK made payments totalling MXN 9,447,264/£ 337,402 to a total of 170 healthcare professionals with an average payment of MXN 55,572/£ 1,984 per HCP.
In 2021, we have paid $7,079,128 MXN to a total number of 139 HCPs with an average payment of $50,929 MXN /HCP.
Media enquiries:
Please contact Emma Prian, Communications and Government Affairs Lead
| Contact details | |
|---|---|
|
Email: |
|
As part of our global corporate commitment to the highest standards of transparency and ethics in our business practices, GSK has decided to disclose payments or transfers of value to healthcare professionals for services provided to GSK, in accordance with the terms of contracts with such third parties. Such services include activities such as speaking at a conference, providing advice as a member of an expert advisory board or as a consultant, as well as travel and accommodation expenses associated with those services.
In 2023, GSK made payments totalling [MAD, 823,474.53 – and £ 66,409.24] to a total of [66] healthcare professionals with an average payment of [MAD, 12,476.88 – and £ 1,006.20] /HCP.
In 2022, GSK made payments totalling MAD 595,204.68/£ 48,000.38 to a total of 21 healthcare professionals with an average payment of MAD 28,334.08/£ 2,285.73 per HCP.
| Year | Report |
|---|---|
| 2023 | PDF (149KB) |
| 2022 | PDF (81KB) |
Media enquiries
Please contact Omar El Mrabet, Director of Pharmaceutical Affairs, Head Pharmacist, Communication & Government Affairs Lead
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for the Netherlands in line with the EFPIA code and Code for Pharmaceutical Advertising (the CGR), and to a note on the methodology used to set out the data in the report. Transfers of value for research and development are not part of the Transparency Register and is therefore listed separately for GSK Netherlands.
https://www.transparantieregister.nl/homepage/zoek-uw-zorgaanbieder
| Year | EFPIA Research Aggregate Disclosure Report |
|---|---|
| 2023 | PDF (91KB) |
| 2022 | PDF (250KB) |
| 2021 | PDF (11KB) |
Media enquiries:
Please contact Central Office
| Contact details | |
|---|---|
|
Tel: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for North Macedonia in line with the EFPIA code.
| Year | Report |
|---|---|
| 2023 |
No transfer of values were made |
| 2022 |
No transfer of values were made |
| 2021 |
No transfer of values were made |
Media enquiries:
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Norway in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Norsk |
|---|---|---|---|
| 2023 | PDF (145KB) | PDF (130KB) | PDF (128KB) |
| 2022 | PDF (150KB) | PDF (171KB) | PDF (149KB) |
| 2021 | PDF (173KB) | PDF (103KB) | PDF (117KB) |
Media enquiries:
Please contact Line Storesund Rondan, Head of Government Affairs and Communication
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
As part of our global corporate commitment to the highest standards of transparency and ethics in our business practices, GSK has decided to disclose payments or transfers of value to healthcare professionals for services provided to GSK, in accordance with the terms of contracts with such third parties. Such services include activities such as speaking at a conference, providing advice as a member of an expert advisory board or as a consultant, as well as travel and accommodation expenses associated with those services.
In 2023, GSK made payments totalling 8,654 OMR (17,740 £) to a total of 29 healthcare professionals with an average payment of 298 OMR (612 £) /HCP.
In 2022, GSK made payments totalling OMR 16,774/£ 35,225 to a total of 19 healthcare professionals with an average payment of OMR 883/£ 1,854 per HCP.
In 2021, we have paid 6,266 OMR to a total number of 8 HCPs with an average payment of 783 OMR per HCP.
| Year | Report |
|---|---|
| 2023 | PDF (99KB) |
| 2022 | PDF (192KB) |
| 2021 | PDF (220KB) |
Media enquiries:
Please contact Averyan Vasylyev, Gulf Cluster Medical Director
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
As part of our global corporate commitment to the highest standards of transparency and ethics in our business practices, GSK has decided to disclose payments or transfers of value to healthcare professionals for services provided to GSK, in accordance with the terms of contracts with such third parties. Such services include activities such as speaking at a conference, providing advice as a member of an expert advisory board or as a consultant, as well as travel and accommodation expenses associated with those services.
In 2023, GSK made payments totalling PKR 8,762,179 – and £35,121 to a total of 102 healthcare professionals with an average payment of PKR 85,904 – and £344.3 /HCP.
In 2022, GSK made payments totalling PKR 1,975,465/£ 8,979.4 to a total of 15 healthcare professionals with an average payment of PKR 131,697.7/£ 598.63 per HCP.
| Year | Report |
|---|---|
| 2023 | PDF (86KB) |
| 2022 | PDF (381KB) |
Media enquiries:
Please contact Sumera Naveed, Director Corporate Governance Affairs & Administration
| Contact details | |
|---|---|
|
Email: |
|
As part of our global corporate commitment to the highest standards of transparency and ethics in our business practices, GSK has decided to disclose payments or transfers of value to healthcare professionals for services provided to GSK, in accordance with the terms of contracts with such third parties. Such services include activities such as speaking at a conference, providing advice as a member of an expert advisory board or as a consultant, as well as travel and accommodation expenses associated with those services.
In 2023, GSK made payments totalling $47,859.20 – £33,006.34 to a total of 28 healthcare professionals with an average payment of $1,709.26 – £1,178.80 /HCP.
In 2022, GSK made payments totalling $6,781.90/£4,677.17 to a total of 9 healthcare professionals with an average payment of $753.5/£519.69 per HCP.
Media enquiries:
Please contact Sabrina Mujica, Communications and Government Affairs Manager
| Contact details | |
|---|---|
|
Email: |
|
As part of our global corporate commitment to the highest standards of transparency and ethics in our business practices, GSK has decided to disclose payments or transfers of value to healthcare professionals for services provided to GSK, in accordance with the terms of contracts with such third parties. Such services include activities such as speaking at a conference, providing advice as a member of an expert advisory board or as a consultant, as well as travel and accommodation expenses associated with those services.
In 2023, GSK made payments totalling PEN 27,700.97 – and £8,969.08 to a total of 9 healthcare professionals with an average payment of PEN 1,846.73 – and £597.94 /HCP.
In 2022, GSK made payments totalling PEN 34,078.27/£7,486.1 to a total of 11 healthcare professionals with an average payment of PEN 2,004.60/£440.36 per HCP.
Media enquiries:
Please contact Mariella Francesca Parodi Soza, Communications & Government Affairs Head
| Contact details | |
|---|---|
|
Email: |
|
As part of our global corporate commitment to the highest standards of transparency and ethics in our business practices, GSK has decided to disclose payments or transfers of value to healthcare professionals for services provided to GSK, in accordance with the terms of contracts with such third parties. Such services include activities such as speaking at a conference, providing advice as a member of an expert advisory board or as a consultant, as well as travel and accommodation expenses associated with those services.
In 2023, GSK made payments totalling ₱ 17,346,982 / £ 266,877 to a total of 694 healthcare professionals with an average payment of ₱ 24,996 / £ 385 per HCP.
In 2022, GSK made payments totalling ₱ 5,169,060/£ 79,560 to a total of 117 healthcare professionals with an average payment of ₱ 44,180/£ 680 per HCP.
In 2021, we paid a total of Php 911.4k to 31 HCPs.
Disclaimer: This is a demonstration of GSK's transparency commitments as a global organization based on its independent selection of in scope activities. As such, the values herein disclosed may vary from GSK Philippines Inc.'s declaration in compliance with the local legal disclosure requirements. Further, no data privacy rights of any HCP has been breached by the foregoing disclosure.
Media enquiries:
Please contact Richard Arboleda, Communications and Government Affairs Head
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Poland in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Polski |
|---|---|---|---|
| 2023 | PDF (319KB) | PDF (159KB) | PDF (306KB) |
| 2022 | PDF (346KB) | PDF (635KB) | PDF (761KB) |
| 2021 | PDF (261KB) | PDF (632KB) | PDF (640KB) |
Media enquiries:
Please contact Małgorzata Stolarczyk-Zdrojkowska
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
In Portugal, GSK strictly complies with the requirements of Portuguese national law (decree number 176/2006) to continuously publish details of all transfers of value with HCOs and HCPs within 30 working days after any payment is made. These disclosures are published and publicly available on the transparency website of Infarmed (Portugal‘s National Authority of Medicines and Health Products / Infarmed - Autoridade Nacional do Medicamento e Produtos de Saúde).
Our disclosures in Portugal via Infarmed include all transfers of value made by GSK to individual HCPs as well as HCOs as required under Portuguese national law.
Media enquiries:
Please contact João Duarte
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
As part of our global corporate commitment to the highest standards of transparency and ethics in our business practices, GSK has decided to disclose payments or transfers of value to healthcare professionals for services provided to GSK, in accordance with the terms of contracts with such third parties. Such services include activities such as speaking at a conference, providing advice as a member of an expert advisory board or as a consultant, as well as travel and accommodation expenses associated with those services.
In 2023, GSK made payments totalling 95,628 QAR (21,038 £) to a total of 23 healthcare professionals with an average payment of 4,158 QAR (915 £) /HCP.
In 2022, GSK made payments totalling QAR 50,721/£ 11,060 to a total of 12 healthcare professionals with an average payment of QAR 4,189/£ 922 per HCP.
In 2021, we have paid 68,267 QAR to a total number of 20 HCPs with an average payment of 3,413 QAR per HCP.
| Year | Report |
|---|---|
| 2023 | PDF (102KB) |
| 2022 | PDF (190KB) |
| 2021 | PDF (226KB) |
Media enquiries:
Please contact Averyan Vasylyev, Gulf Cluster Medical Director
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Romania in line with the EFPIA code and the local legislation requirements.
A distributor EL PHARMA ROMANIA SRL (“Phoenix”) is involved in the promotion of medicines on behalf of GSK in Romania. Transfers of Value made to HCPs / HCOs are reported separately by the local Phoenix entity on Sponsorizari – Medicamente de uz uman – ANMDMR (as per law no 95/2006 and OMS 194/2015) and should be considered together with transfers of value made by GSK directly.
| Year | EFPIA Research Aggregate Disclosure Report |
|---|---|
| 2023 | PDF (101KB) |
| 2022 | PDF (98KB) |
| 2021 | PDF (90KB) |
Media enquiries:
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Russia in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Pусский |
|---|---|---|---|
| 2023 | PDF (113KB) | PDF (93KB) | PDF (140KB) |
| 2022 | PDF (194KB) | PDF (89KB) | PDF (141KB) |
| 2021 | PDF (218KB) | PDF (81KB) | PDF (141KB) |
Media enquiries:
Please contact Olga Korshakova
| Contact details | |
|---|---|
|
Email: |
|
As part of our global corporate commitment to the highest standards of transparency and ethics in our business practices, GSK has decided to disclose payments or transfers of value to healthcare professionals for services provided to GSK, in accordance with the terms of contracts with such third parties. Such services include activities such as speaking at a conference, providing advice as a member of an expert advisory board or as a consultant, as well as travel and accommodation expenses associated with those services.
In 2023, GSK made payments totalling [SAR 5,019,994 – and GBP 1,024,488] to a total of [3166] healthcare professionals with an average payment of [SAR, 1586 – and GBP 324] /HCP.
In 2022, GSK made payments totalling SAR 3,167,722/£ 621,121 to a total of 1663 healthcare professionals with an average payment of SAR 1,905/£ 374 per HCP.
In 2021, we have paid 2,194,725 SAR (623,990 USD) to 1694 HCPs with an average payment of 1,296 SAR (368 USD) per HCP.
Media enquiries:
Please contact Sattam Alghodyyr, Corporate Government Affairs Director
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Serbia and Montenegro in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Srpski |
|---|---|---|---|
| 2023 | PDF (127KB) | PDF (125KB) | PDF (119KB) |
| 2022 | PDF (108KB) | PDF (157KB) | PDF (151KB) |
| 2021 | PDF (106KB) | PDF (104KB) | PDF (113KB) |
Media enquiries:
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Slovakia in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
A distributor PHOENIX Zdravotnicke zasobovanie, a.s. (“Phoenix”) is involved in the promotion of medicines on behalf of GSK in Slovakia. Transfers of Value made to HCPs / HCOs are reported separately by the local Phoenix entity on https://www.nczisk.sk and should be considered together with transfers of value made by GSK directly.
| Year | Report | Methodological Note English | Methodological Note Slovak |
|---|---|---|---|
| 2023 | PDF (106KB) | PDF (142KB) | PDF (131KB) |
| 2022 | PDF (102KB) | PDF (175KB) | PDF (209KB) |
| 2021 | PDF (101KB) | PDF (125KB) | PDF (153KB) |
Media enquiries:
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Slovenia in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Slovenščina |
|---|---|---|---|
| 2023 | PDF (105KB) | PDF (126KB) | PDF (107KB) |
| 2022 | PDF (104KB) | PDF (159KB) | PDF (140KB) |
| 2021 | PDF (101KB) | PDF (105KB) | PDF (104KB) |
Media enquiries:
Please contact Central Office
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Spain in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Español |
|---|---|---|---|
| 2023 | PDF (4.3MB) | PDF (48KB) | PDF (54KB) |
| 2022 | PDF (3.7MB) | PDF (362KB) | PDF (412KB) |
| 2021 | PDF (3.6MB) | PDF (110KB) | PDF (109KB) |
Media enquiries:
Please contact Comms Department
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Sweden in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Svenska |
|---|---|---|---|
| 2023 | PDF (142KB) | PDF (242KB) | PDF (579KB) |
| 2022 | PDF (137KB) | PDF (199KB) | PDF (446KB) |
| 2021 | PDF (142KB) | PDF (110KB) | PDF (334KB) |
Media enquiries:
Please contact Maria Ericson, External Affairs & Market Access Director
| Contact details | |
|---|---|
|
Tel: |
+46 730 33 59 69 |
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Switzerland in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Deutsch | Methodological Note Français |
|---|---|---|---|---|
| 2023 | PDF (358KB) | PDF (182KB) | PDF (230KB) | PDF (273KB) |
| 2022 | PDF (215KB) | PDF (90KB) | PDF (89KB) | PDF (93KB) |
| 2021 | PDF (195KB) | PDF (241KB) | PDF (251KB) | PDF (243KB) |
Media enquiries:
Please contact Urs Kientsch, Corporate Affairs Director or Manuel Mosimann, Communications Manager
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
As part of our global corporate commitment to the highest standards of transparency and ethics in our business practices, GSK has decided to disclose payments or transfers of value to healthcare professionals for services provided to GSK, in accordance with the terms of contracts with such third parties. Such services include activities such as speaking at a conference, providing advice as a member of an expert advisory board or as a consultant, as well as travel and accommodation expenses associated with those services.
In 2023, GSK made payments totalling 31,193,767.47 THB or 693,194.83 £ to a total of 1,723 healthcare professionals with an average payment of 18,104.33 THB or 402.32 £ /HCP.
In 2022, GSK made payments totalling THB 13,037,306/£289,717.92 to a total of 816 healthcare professionals with an average payment of THB 15,977/£355 per HCP.
In 2021, we have paid 102,639 GBP to a total number of 654 HCPs* with an average payment of 157 GBP/HCP.
Media enquiries:
Please contact Supattra Harncharoen, Corporate Affairs Manager
| Contact details | |
|---|---|
|
Email: |
|
As part of our global corporate commitment to the highest standards of transparency and ethics in our business practices, GSK has decided to disclose payments or transfers of value to healthcare professionals for services provided to GSK, in accordance with the terms of contracts with such third parties. Such services include activities such as speaking at a conference, providing advice as a member of an expert advisory board or as a consultant, as well as travel and accommodation expenses associated with those services.
In 2023, GSK made payments totalling $67,063.42 – £46,250.63 to a total of 33 healthcare professionals with an average payment of $2,032.22 – £1,401.53 /HCP.
In 2022, GSK made payments totalling $1,290/£ 889.66 to a total of 1 healthcare professionals with an average payment of $1,290/£889.66 per HCP.
Media enquiries:
Please contact Sabrina Mujica, Communications and Government Affairs Manager
| Contact details | |
|---|---|
|
Email: |
|
As part of our global corporate commitment to the highest standards of transparency and ethics in our business practices, GSK has decided to disclose payments or transfers of value to healthcare professionals for services provided to GSK, in accordance with the terms of contracts with such third parties. Such services include activities such as speaking at a conference, providing advice as a member of an expert advisory board or as a consultant, as well as travel and accommodation expenses associated with those services.
In 2023, GSK made payments totalling ₺45,169,759.14 – £1,090,495.93 to a total of 6,885 healthcare professionals with an average payment of ₺6,560.60 – £158.39
/HCP.
In 2022, GSK made payments totaling ₺15,970,658.48 - £539,002.99 to a total of 3,831 healthcare professionals with an average payment of ₺4,168.80 - £140.70 / HCP.
Media enquiries:
Please contact Zeynep Birgül, Communications & Patient Relations Manager
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Ukraine in line with the EFPIA code and APRaD, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Ukrainian |
|---|---|---|---|
| 2023 | PDF (128KB) | PDF (161KB) | PDF (202KB) |
| 2022 | PDF (118KB) | PDF (161KB) | PDF (204KB) |
| 2021 | PDF (123KB) | PDF (159KB) | PDF (251KB) |
Media enquiries:
Please contact Olga Vorobiova, CTC & Distribution Head
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
GSK is committed to disclosing the payments we make, as we work together with healthcare professionals. Our payments to HCPs include the provision of services such as giving a lecture, attending/ supporting educational meetings, providing advice as a member of an Advisory Board or as a Consultant, as well as travel and accommodation expenses associated with those services. GSK’s voluntary decision to publish our payments to HCPs is part of our commitment to greater transparency and high ethical standards in our business practices.
In 2023, GSK made payments totalling 1,956,818 AED (410,932 £) to a total of 327 healthcare professionals with an average payment of 5,984 AED (1,257 £) /HCP.
In 2022, GSK made payments totalling AED 780,835/£171,784 to a total of 109 healthcare professionals with an average payment of AED 7,164/£1,576 per HCP.
In 2021, we have paid 329,937 AED to a total number of 62 HCPs with an average payment of 5,322 AED per HCP.
Media enquiries:
Please contact Averyan Vasylyev, Gulf Cluster Medical Director
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for United Kingdom in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English |
|---|---|---|
| 2023 | PDF (1MB) | PDF (150KB) |
| 2022 | PDF (809KB) | PDF (193KB) |
| 2021 | PDF (701KB) | PDF (149KB) |
Media enquiries:
Please contact UK Office
| Contact details | |
|---|---|
|
Email: |
|
As part of our global corporate commitment to the highest standards of transparency and ethics in our business practices, GSK has decided to disclose payments or transfers of value to healthcare professionals for services provided to GSK, in accordance with the terms of contracts with such third parties. Such services include activities such as speaking at a conference, providing advice as a member of an expert advisory board or as a consultant, as well as travel and accommodation expenses associated with those services.
In 2023, GSK made payments totalling [10,181,293,808.96 ₫ – and £ 305,048.35] to a total of 1459 healthcare professionals with an average payment of [6,978,268.55 ₫ – and £ 209.08] /HCP.
In 2022, GSK made payments totalling ₫ 4,165,080,739.05/£ 124,792.69 to a total of 616 healthcare professionals with an average payment of ₫ 6,761,494.71/£ 202.59 per HCP.
| Year | Report |
|---|---|
| 2023 | PDF (531 KB) |
| 2022 | PDF (209KB) |
Disclaimer: Travel and accommodation expenses are paid to GSK’s event organiser and not to HCPs.
Media enquiries:
Please contact Phuong Pham, Communication Lead
| Contact details | |
|---|---|
|
Email: |
|
|
|
Diem Nguyen Nhu Phuc: diem.p.nguyen-nhu@gsk.com |
